Together, we will continue scaling up our activities in the countries of Central Asia. The role of Reka-Med is a production site that will meet the demand for YURіА-PHARM products…
Investment of 350 million EUR in state-of-the-art research infrastructure is Boehringer Ingelheim’s largest single investment in Germany to date Boehringer Ingelheim strengthens innovation power and development of biopharmaceuticals, which account…